Comprehensive Appeal Guide: HCPCS J1745 (Infliximab, Excludes Biosimilar)

1. Introduction

HCPCS J1745 describes injection, infliximab, excludes biosimilar, 10 mg — the brand-name biologic Remicade administered in a clinical setting. Because J1745 is billed per 10 mg unit, the units on the claim equal the dose in milligrams divided by 10: a 350 mg infusion is billed as 35 units. Remicade comes in 100 mg single-dose vials (prescribing information), so any drug left in the last vial also has to be accounted for on the claim.

Infliximab is a TNF-alpha inhibitor used across several FDA-approved indications including Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. Payers review J1745 claims closely in hospital outpatient departments, infusion suites and physician offices, and many steer new starts toward an infliximab biosimilar.

Denials happen for many reasons — step therapy failures, biosimilar substitution pressure, authorization lapses, or simple coding errors — and the financial stakes per claim can be high. This guide provides a practical, payer-specific roadmap for winning those appeals.

2. Common Denial Reasons

Understanding why J1745 gets denied is the foundation of every successful appeal. The seven most common denial categories are:

1. No Prior Authorization / Authorization Not Obtained — Commercial, Medicare Advantage and Medicaid plans commonly require prior authorization for infliximab; Traditional Medicare generally does not use prior authorization for Part B drugs. Claims submitted without a valid auth, or after auth expiration, are routinely denied.

2. Step Therapy / Fail-First Requirements Not Met — Most payers require documented failure of conventional therapies (e.g., corticosteroids, immunomodulators, MTX) and sometimes one or more TNF-alpha inhibitors before approving J1745.

3. Biosimilar Substitution Denial — Because J1745 explicitly excludes biosimilar, many payers require an FDA-approved infliximab biosimilar first, especially for new starts. A claim for J1745 may be denied with a redirect to a biosimilar HCPCS code (e.g., Q5103, Q5121).

4. Diagnosis Not Covered / Medical Necessity Not Established — The submitted ICD-10 diagnosis may not match the payer's covered indications, or the clinical record may lack sufficient documentation of disease severity.

5. Units Billed Incorrectly — J1745 is billed per 10 mg. Billing errors (e.g., billing total dose instead of units, or miscalculating weight-based dosing) trigger automatic denials or audits.

6. Site of Service Issues — Some payers restrict infliximab infusions to specific sites (e.g., home infusion or outpatient hospital vs. physician office) and deny claims from non-preferred settings.

7. Lack of Specialist Involvement / Documentation Gaps — Payers often require that a board-certified specialist (gastroenterologist, rheumatologist, dermatologist) manage the therapy, and that clinical notes reflect ongoing disease assessment.

3. Payer-Specific Requirements

Commercial Plans (Aetna, Anthem / Elevance Health, BCBS Plans, Cigna, UnitedHealthcare)

Medical Policy Criteria
Each commercial payer publishes its own infliximab policy, and Blue Cross Blue Shield plans are independent companies with their own policies. Common elements include a labeled indication, moderate-to-severe disease documented in the record, prior conventional therapy, specialist management, and, for renewals, documented response. Many plans also require a biosimilar first for new starts, and some direct the drug through a specialty pharmacy rather than buy-and-bill. The specifics vary by payer, plan and state, so pull the current policy the denial cites.

Required Documentation

• Letter of medical necessity from the treating specialist
• Disease severity scoring appropriate to the condition (for example CDAI, DAS28 or the Harvey-Bradshaw Index)
• Prior therapies with dates, doses, duration and the reason each was stopped
• Current weight, for weight-based dose verification
• The authorization number on the claim, and the NDC if the plan requires it
• For continuation: objective response or stability, at baseline and now

Tips

• Map the record to each criterion in the policy, point by point.
• For a biosimilar-first denial, document any prior biosimilar trial, allergy or intolerance, and whether the patient is already stable on the reference product; check whether the policy has a continuation-of-therapy provision.
• Confirm the plan's required acquisition channel (buy-and-bill or specialty pharmacy) and site of care before the drug is ordered.
• For employer group plans, the federal claims rule (29 CFR 2560.503-1) entitles the claimant to copies of the documents relevant to the claim, and to any internal rule or guideline the plan relied on, free of charge on request.
• For members in these payers' Medicare Advantage plans, follow the Medicare Advantage section below.

Medicare Advantage Plans (Humana, UnitedHealthcare, Aetna and Others)

Medical Policy Criteria
A Medicare Advantage plan must cover everything Traditional Medicare covers and must follow national coverage determinations and the LCDs of the local Medicare contractor (42 CFR 422.101). It may use its own published internal criteria only where Medicare coverage criteria are not fully established. MA plans can require prior authorization, and they can apply step therapy to Part B drugs such as infliximab, but only to new administrations, using a lookback of at least 365 days (42 CFR 422.136). A patient who already received the drug within the lookback period is not a new administration.

Required Documentation

• The authorization request with all clinical questions answered
• Specialist notes and supporting results (for example CRP, ESR, RF or anti-CCP for RA; endoscopy reports for IBD)
• For a step-therapy denial: infusion records showing the patient received infliximab within the lookback period, if that is the case

Tips

• Confirm whether the member's plan is commercial or Medicare Advantage; the appeal path differs.
• Request an expedited reconsideration if waiting could seriously jeopardize the patient's health, for example a patient mid-treatment.
• An enrollee, or a non-contracted provider with a waiver of liability, requests reconsideration within 65 days of the notice. If the plan upholds its denial, it forwards the case automatically to the Independent Review Entity. Contracted providers' payment disputes follow their contract.

Medicare Traditional (Parts A & B)

Medical Policy Criteria
Under Part B, J1745 is covered as a drug administered in a physician office or hospital outpatient department when it is reasonable and necessary. Traditional Medicare does not impose biosimilar step therapy; check whether your MAC has an LCD or billing article that applies. In a physician office the infusion is billed under the incident-to rules, including their supervision requirements.

Required Documentation

• The ICD-10 diagnosis code linked to J1745
• Correct units (dose in mg divided by 10)
• Documentation of medical necessity in the medical record
• Incident-to requirements met if billed by a physician practice
• The JW modifier on a separate line for drug discarded from the single-dose vials, or the JZ modifier when nothing was discarded

Key Differences
Traditional Medicare does not require prior authorization for most Part B drug claims, so the claim itself is where coverage is decided, and it can be reviewed after payment. The JZ modifier has been required since July 1, 2023 on claims for drugs from single-dose containers when no amount was discarded (CMS).

Tips

• Check the units: dose (mg) ÷ 10 = units to bill. Document the exact mg administered and any amount discarded.
• Make sure the practitioner NPIs are on the claim and that supervision requirements are met.
• Medicare Advantage plans are not commercial plans: they must cover everything Traditional Medicare covers and follow NCDs and LCDs, and their appeals go through the Medicare Advantage reconsideration process described above.
• Request a redetermination within 120 days of receiving the initial determination (receipt is presumed 5 days after the notice date).

Medicaid Managed Care Plans (Molina Healthcare and Others)

Medical Policy Criteria
Each state sets Medicaid coverage for infliximab, and a managed care plan such as Molina applies the state's rules along with its own prior authorization requirements. Some states apply preferred-product rules, including biosimilar preferences, to physician-administered drugs. Molina also offers Marketplace and Medicare plans; for those members, use the commercial or Medicare Advantage guidance above.

Required Documentation

• The state or plan prior authorization approval
• Clinical notes confirming the indication and severity
• Prior therapies tried, per the state's criteria

Tips

• Check the state's Medicaid policy and the plan's provider manual, and frame the appeal on the state's clinical criteria.
• Under federal rules, an enrollee has 60 calendar days from the date on the adverse benefit determination notice to appeal to the plan, and a provider can file for the enrollee with the enrollee's written consent where state law permits (42 CFR 438.402). Provider payment disputes follow state rules and the plan contract, and those windows vary by state and plan.
• If the plan upholds its denial, the enrollee can request a state fair hearing.

4. Required Documentation Checklist

Regardless of payer, every J1745 appeal should include:

• ☐ Complete medical records — specialist notes documenting diagnosis, severity, and treatment history (minimum 3–6 months)
• ☐ Objective disease severity scoring — validated tools appropriate to the condition (CDAI, PUCAI, DAS28, PASI, BASDAI, etc.)
• ☐ Step therapy documentation — dates, drugs, doses, duration, and documented reason for failure/discontinuation of each prior agent
• ☐ Letter of medical necessity — signed by the treating specialist, specific to infliximab (J1745), with clinical rationale
• ☐ Prior authorization approval documentation (if applicable — copy of the approval with auth number)
• ☐ Infusion administration records — confirming dose administered, date, and supervising provider
• ☐ NDC number for infliximab — confirming the non-biosimilar product was dispensed
• ☐ Claim copy (CMS-1500 or UB-04) — showing J1745, correct units, diagnosis codes, and provider information
• ☐ Explanation of Benefits (EOB) or Remittance Advice — showing the specific denial reason code and remark code
• ☐ Published clinical literature (for biosimilar-switching or complex medical necessity arguments)
• ☐ Patient history of biosimilar failure or contraindication (if biosimilar-first denial)

5. Sample Appeal Arguments

Argument 1: Established Clinical Response — Continuation of Therapy

"The patient has been receiving infliximab (J1745) for [X months/years] with documented clinical remission as evidenced by [objective measure]. The treating physician has determined that changing therapy in this clinically stable patient is not appropriate because [patient-specific clinical rationale, for example prior loss of response after a therapy change, documented anti-drug antibodies, or disease history], supported by [cite the specific guideline or published evidence relied on]."

Argument 2: Step Therapy Fully Satisfied

"Prior to initiating infliximab (J1745), the patient completed a documented trial of [Agent A, dates, dose, outcome] and [Agent B, dates, dose, outcome], both of which were discontinued due to [inadequate response/intolerance/contraindication]. All step therapy requirements outlined in the payer's medical policy have been satisfied. Continued denial constitutes a barrier to medically necessary care."

Argument 3: Biosimilar Contraindication / Prior Biosimilar Failure

"The plan's biosimilar-first requirement is not clinically appropriate for this patient because [the patient previously failed biosimilar X / the patient has a documented allergy or intolerance / the treating physician has determined that non-medical switching poses unacceptable clinical risk]. HCPCS J1745 describes injection, infliximab, excludes biosimilar, 10 mg — the specific product medically indicated for this patient."

Argument 4: Units and Medical Necessity Are Clinically Supported

"The claim was submitted for [X] units of J1745 (infliximab, excludes biosimilar, 10 mg per unit), reflecting a total dose of [X mg] calculated at [X mg/kg] for a patient weighing [X kg]. This dose is consistent with FDA-approved labeling for [indication], current clinical guidelines, and the patient's documented response history. The units billed are accurate and medically necessary."

6. Filing Deadlines

Always check the provider contract and the denial notice for the deadline that applies. The ALJ and federal court levels have amount-in-controversy thresholds that change every year. Medicare Advantage plans decide standard reconsiderations of a Part B drug request within 7 days, other pre-service requests within 30 days, payment reconsiderations within 60 days and expedited requests within 72 hours (42 CFR 422.590).